Brookline Capital Management Brokers Increase Earnings Estimates for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Investment analysts at Brookline Capital Management increased their Q1 2024 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a report issued on Wednesday, March 27th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of ($0.74) for the quarter, up from their previous forecast of ($0.94). The consensus estimate for Syros Pharmaceuticals' current full-year earnings is ($3.75) per share. Brookline Capital Management also issued estimates for Syros Pharmaceuticals' Q2 2024 earnings at ($0.77) EPS, Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.99) EPS, FY2024 earnings at ($3.24) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at $1.68 EPS and FY2027 earnings at $6.91 EPS.

Separately, StockNews.com upgraded Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday.

Syros Pharmaceuticals Stock Performance

SYRS stock traded down $0.49 during trading hours on Friday, hitting $5.35. 318,254 shares of the stock were exchanged, compared to its average volume of 187,515. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $112.72 million, a P/E ratio of -0.93 and a beta of 1.79. The company has a 50-day simple moving average of $6.84 and a two-hundred day simple moving average of $5.07. Syros Pharmaceuticals has a 12 month low of $2.09 and a 12 month high of $8.17.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SYRS. Two Sigma Investments LP boosted its stake in Syros Pharmaceuticals by 30.0% in the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company's stock valued at $36,000 after buying an additional 3,139 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Syros Pharmaceuticals by 8.0% during the fourth quarter. Renaissance Technologies LLC now owns 47,235 shares of the company's stock valued at $170,000 after purchasing an additional 3,500 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Syros Pharmaceuticals by 85.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,550 shares of the company's stock valued at $61,000 after purchasing an additional 10,400 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Syros Pharmaceuticals by 13.1% during the second quarter. LPL Financial LLC now owns 94,075 shares of the company's stock valued at $296,000 after purchasing an additional 10,886 shares in the last quarter. Finally, Shay Capital LLC boosted its stake in shares of Syros Pharmaceuticals by 87.3% during the second quarter. Shay Capital LLC now owns 26,426 shares of the company's stock valued at $83,000 after purchasing an additional 12,317 shares in the last quarter. Institutional investors own 91.47% of the company's stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.